Clovis Oncology - Verdoppler an einem Tag!
Seite 1 von 4
neuester Beitrag: 13.11.19 17:38
|eröffnet am:||03.06.13 22:36 von:||Balu4u||Anzahl Beiträge:||82|
|neuester Beitrag:||13.11.19 17:38 von:||Balu4u||Leser gesamt:||16658|
|bewertet mit 1 Stern
Balu4u : Clovis Oncology - Verdoppler an einem Tag!
Vassago : CLVS 4,59$ (-3%)
Clovis erwirbt für 12 Mio. $ Cash einen präklinischen Produktkandidaten um die Pipeline zu erweitern
- MK 251 Mio. $
Vassago : CLVS 4,18$ (-2%)
Vassago : CLVS 5,26$ (+22%)
finanziert bis in die zweite Hälfte 2021
"Clovis had $354.1 million in cash, cash equivalents and available-for-sale securities as of September 30, 2019. In August 2019, Clovis completed a private placement sale of $263.0 million aggregate principal amount of 4.50 percent convertible senior notes due 2024. The net proceeds from the offering were $255.0 million, after deducting underwriting discounts and commissions, and offering expenses. A portion of the proceeds, totaling $171.8 million, were used to repurchase $190.3 million of par value of convertible senior notes due 2021, with the remainder of $83.2 million to be used for general corporate purposes. As of September 30, 2019, the Company also had up to $154 million remaining to draw under the TPG ATHENA clinical trial financing agreement to fund the expenses of the ATHENA trial through Q3 2022.
Based on the Company?s anticipated revenues, spending, available financing sources and existing cash, cash equivalents and available-for-sale securities, the Company believes it has sufficient cash, cash equivalents and available-for-sale securities to fund its operating plan into the second half of 2021. This does not include any cash repayment that may be required to pay off (unless refinanced earlier) the remaining $97 million principal amount of convertible notes at their maturity due September 2021."